Weight Regain After Stopping Tirzepatide Proportionally Reverses Metabolic Improvements
After tirzepatide withdrawal, 75%+ weight regain occurred in most patients within 1 year, with cardiometabolic improvements (waist, BP, HbA1c, insulin) reversing proportionally to weight regain degree.
Quick Facts
What This Study Found
After tirzepatide withdrawal, weight regain ≥75% in most patients within 1 year. Cardiometabolic reversal proportional to regain: waist (+0.8 to +14.7 cm), SBP (+6.8 to +10.4 mmHg), HbA1c (+0.14 to +0.35%), fasting insulin (-4% to +46%) across <25% to ≥75% regain categories.
Key Numbers
How They Did This
Post-hoc analysis of SURMOUNT-4 RCT (NCT04660643), 308 tirzepatide-treated participants (≥10% weight loss at wk 36) randomized to placebo, categorized by weight regain degree at wk 88.
Why This Research Matters
This provides the most detailed look at what happens after stopping tirzepatide — showing that metabolic benefits are proportionally lost with weight regain.
The Bigger Picture
This definitively shows GLP-1/GIP drugs treat obesity but don't cure it — withdrawal leads to proportional reversal, like stopping blood pressure medication.
What This Study Doesn't Tell Us
Post-hoc analysis. 52-week withdrawal period. Selection bias possible in regain categories.
Questions This Raises
- ?What determines which patients regain less weight?
- ?Could intermittent dosing maintain some benefits?
- ?Should tirzepatide be considered lifelong therapy for all patients?
Trust & Context
- Key Stat:
- Proportional reversal Metabolic improvements from tirzepatide reversed in direct proportion to weight regain after stopping: <25% regain preserved gains, ≥75% regain erased them
- Evidence Grade:
- Post-hoc analysis of landmark RCT. Well-powered with clear dose-response relationship between regain and metabolic reversal.
- Study Age:
- Published in 2025 from SURMOUNT-4 data.
- Original Title:
- Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
- Published In:
- JAMA internal medicine, 186(2), 157-167 (2026)
- Authors:
- Horn, Deborah B(3), Linetzky, Bruno(2), Davies, Melanie J(13), Laffin, Luke J, Wang, Hui, Murphy, Madhumita A, Zimner-Rapuch, Sarah, Lau, Eva, Arad, Avigdor D, Lee, Clare J
- Database ID:
- RPEP-15307
Evidence Hierarchy
Frequently Asked Questions
What happens when you stop tirzepatide?
Most patients regain at least 25% of lost weight within a year, and their metabolic improvements reverse proportionally. Those who regain the most weight lose nearly all the metabolic benefits.
Does this mean I need to take it forever?
Current evidence suggests yes — like blood pressure medication, stopping tirzepatide leads to return of the underlying condition. Patients who maintained the most weight loss had the best metabolic outcomes.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15307APA
Horn, Deborah B; Linetzky, Bruno; Davies, Melanie J; Laffin, Luke J; Wang, Hui; Murphy, Madhumita A; Zimner-Rapuch, Sarah; Lau, Eva; Arad, Avigdor D; Lee, Clare J. (2026). Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.. JAMA internal medicine, 186(2), 157-167. https://doi.org/10.1001/jamainternmed.2025.6112
MLA
Horn, Deborah B, et al. "Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.." JAMA internal medicine, 2026. https://doi.org/10.1001/jamainternmed.2025.6112
RethinkPeptides
RethinkPeptides Research Database. "Cardiometabolic Parameter Change by Weight Regain on Tirzepa..." RPEP-15307. Retrieved from https://rethinkpeptides.com/research/horn-2026-cardiometabolic-parameter-change-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.